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Activation of RARα induces autophagy in SKBR3 breast
cancer cells and depletion of key autophagy genes
enhances ATRA toxicity
D Brigger1,2,4, AM Schläfli1,2,4, E Garattini3 and MP Tschan*,1,2
All-trans retinoic acid (ATRA), a pan-retinoic acid receptor (RAR) agonist, is, along with other retinoids, a promising therapeutic
agent for the treatment of a variety of solid tumors. On the one hand, preclinical studies have shown promising anticancer effects
of ATRA in breast cancer; on the other hand, resistances occurred. Autophagy is a cellular recycling process that allows the
degradation of bulk cellular contents. Tumor cells may take advantage of autophagy to cope with stress caused by anticancer
drugs. We therefore wondered if autophagy is activated by ATRA in mammary tumor cells and if modulation of autophagy might be
a potential novel treatment strategy. Indeed, ATRA induces autophagic flux in ATRA-sensitive but not in ATRA-resistant human
breast cancer cells. Moreover, using different RAR agonists as well as RARα-knockdown breast cancer cells, we demonstrate that
autophagy is dependent on RARα activation. Interestingly, inhibition of autophagy in breast cancer cells by either genetic or
pharmacological approaches resulted in significantly increased apoptosis under ATRA treatment and attenuated epithelial
differentiation. In summary, our findings demonstrate that ATRA-induced autophagy is mediated by RARα in breast cancer cells.
Furthermore, inhibition of autophagy results in enhanced apoptosis. This points to a potential novel treatment strategy for a
selected group of breast cancer patients where ATRA and autophagy inhibitors are applied simultaneously.
Cell Death and Disease (2015) 6, e1861; doi:10.1038/cddis.2015.236; published online 27 August 2015
Macroautophagy (hereafter referred to as autophagy) is a
conserved mechanism characterized by the formation of
double-membrane structures. These so-called autophago-
somes deliver cytoplasmic material to the lysosome for
subsequent degradation.1 Basal autophagy requires tight
regulation as alterations in autophagy have been associated
with many pathological conditions, including cancer.2 In
addition, autophagy has been linked to fundamental
processes such as development and cellular differentiation.
In these processes, autophagy contributes to cell remodeling
as observed during erythrocyte, lymphocyte or adipocyte
differentiation.3 In the context of cancer and cancer therapy,
autophagy is a double-edged sword. Owing to its homeostatic
role in the removal of potentially harmful damaged organelles
and protein aggregates, it is suggested to be tumor suppres-
sive under normal conditions.4 In cancer cells, however,
autophagy can be oncogenic, enabling survival under stress-
ful conditions.5 Hence, the role of autophagy in tumorigenesis
is clearly dependent on the cellular context and the tumor
stage. In some cases, therapeutic agents induce an autopha-
gic response that can promote resistance to treatment.
In other cases, autophagy contributes to the action of
antitumor agents.6 Therefore, knowledge about the action
exerted by autophagy in response to anticancer treatments is
a prerequisite for the identification of patients benefiting from
therapeutic strategies based on autophagy modulators.
All-trans retinoic acid (ATRA), the active metabolite of
vitamin A, exerts diverse functions in almost every cell and
organ system. ATRA controls cell proliferation, differentiation
as well as immune, and neuronal functions primarily via
regulation of gene expression.7 Endogenous retinoid levels
are altered in different diseases of the lung, kidney and central
nervous system, and contribute to their pathophysiology.8
ATRA is successfully used in the treatment of acute
promyelocytic leukemia (APL), where it induces granulocytic
differentiation of the blast and subsequent cell death of the
differentiated leukemic cells. Importantly, ATRA-induced
differentiation of the APL cell line, NB4, involves induction of
macroautophagy.9–12 In addition to its cytodifferentiating
capacity in APL, ATRA has been proposed as an antitumori-
genic agent for other types of cancer. The antiproliferative,
cytodifferentiating and proapoptotic effects of retinoids are
predominantly mediated by the nuclear hormone retinoid acid
receptors RARα, RARβ and RARγ.13,14 In breast cancer,
preclinical studies have shown that retinoids are promising
therapeutic agents. However, the clinical trials conducted so
far were somewhat disappointing, possibly as a consequence
of the study designs.15 Breast cancer is a highly
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heterogeneous disease represented as a collection of
diseases with distinct histopathological and molecular fea-
tures. The most important clinical classification of this tumor is
based on the determination of ER (estrogen receptor), PR
(progesterone receptor) and HER2 (human epidermal growth
factor receptor-2) receptors. ER-positive breast cancer
patients are eligible for hormonal therapies, whereas HER2
oncogenic activity can be blocked using targeted therapies.16
Approximately 15–20% of breast carcinomas overexpress
HER2, which is associated with poor prognosis.17 Owing to
the development of resistance to current HER2-targeted
treatments such as trastuzumab and lapatinib alternative
therapeutic strategies are required.18,19 ATRA was recently
shown to exert strong antitumor activity in cell lines represent-
ing a subgroup of HER2-positive breast tumors characterized
by coamplification of the ERBB2 and RARα genes.20 This
antitumor activity is remarkably stimulated by simultaneous
HER2 inhibition with lapatinib. In addition, autophagy is
induced upon ATRA treatment of the APL-derived cell line
NB49–11 and retinoids have clinical relevance in breast cancer.
Thus, we investigated whether and how autophagy is induced
in breast cancer cells. In addition, we evaluated whether
autophagy modulation represents a potential therapeutic
strategy for potentiating ATRA cytotoxicity in breast
cancer cells.
Results
ATRA initiates a dose- and time-dependent autophagic
response associated with epithelial differentiation in
SKBR3 cells. To determine whether ATRA modulates
autophagy in breast cancer cells, we first measured steady-
state levels of the autophagy marker LC3B-II in the two
luminal, HER2-positive ER-negative breast cancer cell lines,
SKBR3 (HER2/RARα coamplification) and MDA-MB453
(HER2 amplification), upon challenge with different concen-
trations of ATRA during different time periods. We chose
these two cell lines as SKBR3 are sensitive to and
MDA-MB453 cells are resistant to ATRA.20 In the SKBR3
cells, we observed a dose-dependent increase in the steady-
state levels of lipidated LC3B (LC3B-II), which was paralleled
by induction of the differentiation-associated β-catenin
protein. These effects were not observed in ATRA-treated
MDA-MB453 cells (Figures 1a and b). ATRA-dependent
cytodifferentiation was further visualized at day 2, using
immunofluorescence microscopy to highlight the redistribu-
tion of β-catenin to the cell membrane where it contributes to
epithelial differentiation.20 ATRA treatment of SKBR3 clearly
caused relocalization of β-catenin to the cell membrane.
Regardless of ATRA treatment, MDA-MB453 cells showed a
punctuated perinuclear distribution with no membrane
localization of β-catenin20 (Figure 1c).
To further quantify autophagy induction in our cell line
models, we determined endogenous LC3B puncta by confocal
microscopy. We observed a significant increase in endogen-
ous LC3B puncta in SKBR3 but not in MDA-MB453 cells
(Figure 1d and Supplementary figure 1a). Given the significant
induction of LC3B-II (Figures 1a and b), we next monitored
autophagic flux to exclude that a block in the autophagy
pathway causes LC3B-II accumulation. We therefore quanti-
fied lipidated LC3B levels in the presence and absence of a
saturating lysosomal inhibitor, bafilomycin A1 (BafA). ATRA-
induced LC3B lipidation, which was significantly enhanced in
the presence of BafA, suggests increased autophagic flux. In
contrast, ATRA administration did not result in a further
increase beyond basal autophagy levels in the MDA-MB453
cell line (Figure 1e). As autophagy must be evaluated using
different techniques,21 we also used a standard biochemical
method to determine autophagic activity. We measured the
turnover of long-lived 14C-valine-labeled proteins upon 2 days
of ATRA treatment of SKBR3 and MDA-MB453 cells in the
presence or absence of the autophagy inhibitor BafA. In
SKBR3 cells, the proteolysis of long-lived proteins was
significantly increased by ATRA, whereas no such increase
was observed in MDA-MB453 cells (Figure 1f). Moreover,
3-methyladenine (3-MA) blocked ATRA-mediated autophagy
as efficiently as BafA, indicating that retinoids preferentially
induce macroautophagy in retinoid-sensitive breast cancer
cells (Figure 1g). As a third assay to assess autophagic flux in
our breast cancer cells, we took advantage of a Cherry-GFP-
LC3B tandem construct. As the GFP signal is quenched at low
pH, this system allows to distinguish between autophago-
somes (Cherry+/GFP+) and autolysosomes (Cherry+).22 ATRA
treatment caused an increase of Cherry+/GFP+ dots aswell as
Cherry+ dots in SKBR3 cells clearly indicating activation of
autophagic flux (Figure 2, upper panel). In contrast, ATRA
treatment caused a decrease in the number of autophago-
somes (Cherry+/GFP+) and autolysosmes (Cherry+) over time
in MDA-MB453 cells. Altogether, these different standard
assays to monitor autophagy convincingly demonstrate that
ATRA activates autophagic flux in ATRA-sensitive SKBR3 but
not in ATRA-resistant MDA-MB453 cells.
ATRA-induced autophagy flux depends on RARα. As we
observed increased autophagic flux only in ATRA-sensitive
cells, we were interested in the signal-transduction mechan-
ism leading to the observed phenotype. We focused on the
main retinoic acid effectors, that are, the nuclear retinoid
receptors, RARα, RARβ and RARγ. To this end, we treated
SKBR3 cells with RARα, RARβ and RARγ agonists alone and
in combination with BafA and determined LC3B puncta
formation (Figures 3a and b). Quantification of the number of
dots per cells revealed a significant increase of autophagic
activity only when SKBR3 cells where subjected to the RARα
agonist AM580 (4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthalenyl)carbonyl]amino]-benzoic acid; Figures 3b and c).
To validate the LC3B immunofluorescence data, we addition-
ally performed long-lived protein degradation assays. In
agreement with the immunofluorescence data, only the
specific RARα agonist, AM580, significantly increased
autophagic-dependent degradation of 14C-valine-labeled
proteins (Figure 3d). As a third method to determine
autophagic flux, LC3B-II western blot was performed
(Figures 3e and f). Again, increased autophagic flux was
seen only upon RARα but not upon RARβ or RARγ activation
(Figures 3e and f). These results reinforce the notion that
RARα is the limiting nuclear receptor in the induction of
autophagic flux by retinoic acid. It is worth mentioning that
autophagy induction by AM580 was paralleled by induction of
Retinoid-induced autophagy in breast cancer cells
D Brigger et al
2
Cell Death and Disease
the differentiation markers β-catenin and VE-cadherin
(Figure 3e). To support our hypothesis that autophagy is
mediated by RARα, we depleted RARα in SKBR3 cells. As
observed by Bosh et al.,13 knocking down RARα changed the
cell morphology to a spindle-like shape (data not shown).
Depletion of RARα prevented the ATRA-dependent increase
in β-catenin and VE-cadherin, confirming that RARα
activation is key to cytodifferentiation (Figure 4a).20 In
addition, ATRA-dependent cell membrane relocalization of
β-catenin observed in control transduced cells was reduced
in SKBR3 RARα knockdown cells (Figure 4b). Although
RARα depletion did not affect the basal autophagy levels, it
significantly blocked LC3B mRNA induction as well as LC3B-
II turnover following ATRA treatment (Figures 4c and d).
d4d2d4
1
d2
*** ***
***
5
10
15
0
0 0 1
-
-
-
+
-
-
-
+
-
-
-
+
+
-
+
-
+
+
1 1
0 
d2
1 1
d4
0
200
400
600
800
- d2 - d2
****
ns
5
10
15
0
**
**
ns
CTRL
*
* 
* 
0 
d2
1 1
d4
-
- + +
-
-
+ ++
- + +
- -
-
+
0
20
40
60
ATRA [M]
ATRA [M]
0.1
0.1 0.1 0.1 0.1
0.10.10.1
SKBR3 MDA-MB453
-catenin
LC3B-II
(low exp.)
LC3B-I
GAPDH 
LC3B-II
(high exp.) 
MDA-MB453SKBR3
LC
3B
-II
/G
AP
DH
 (%
)
* unspecific
ATRA
SK
BR
3
M
D
A
-M
B
45
3
900 
1200 
0 
**
*
600 
300 
- + +
- -
-
+ +
- + +
- -
-
+ +
LC
3B
-II
/G
AP
DH
 (%
) 
MDA-MB453SKBR3
BafA
ATRA
GAPDH 
LC3B-II 
LC3B-I
#L
C3
B 
pu
nc
ta
 / 
ce
ll
ATRA
%
 P
ro
te
ol
ys
is
BafA
ATRA
MDA-MB453SKBR3
BafA
3-MA
ATRA
SKBR3
%
 P
ro
te
ol
ys
is
-catenin
Figure 1 ATRA induces autophagy in SKBR3 cells. (a) SKBR3 and MDA-MB-453 breast cancer cells were treated either with 0.1 or 1 μM ATRA for 2 and 4 days, respectively.
β-Catenin and LC3B levels were measured by western blotting. GAPDH was used as a loading control. (b) LC3B-II quantification from at least three independent experiments.
LC3B-II expression was normalized to GAPDH and to vehicle-treated SKBR3 cells. (c) β-Catenin staining of SKBR3 and MDA-MB453 cells. Cells were control or ATRA (1 μM)
treated for 2 days. β-Catenin FITC (fluorescein isothiocyanate) and nuclear DAPI (4',6-diamidino-2-phenylindole) staining as analyzed by confocal microscopy are shown.
(d) Quantification of endogenous LC3B puncta. LC3B in SKBR3 and MDA-MB453 cells treated with 1 μM ATRA for 2 days. (e) LC3B-II western blotting and quantification of the
autophagic activation upon treatment with 1 μM ATRA for 2 days in the presence or absence of BafA for 2 h at 200 nM. LC3B-II levels were normalized to GAPDH and to vehicle-
treated SKBR3 cells. Standard deviations for five independent experiments are shown. (f) Long-lived protein degradation assay of SKBR3 and MDA-MB453 cells treated as in
(e). Radioactivity was determined by liquid scintillation counting of at least three independent experiments. Absolute proteolysis is shown. (g) Long-lived protein degradation
assay of SKBR3 treated as in (e) and including treatment with the macroautophagy-specific inhibitor 3-MA (10 mM). Analysis as in (f). Mann–Whitney U-test: *Po0.05,
**Po0.01, ***Po0.001 and ****Po0.0001
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Finally, RARα depletion significantly decreased BafA- and 3-
MA-dependent degradation of long-lived proteins in ATRA-
treated cells (Figure 4e). Taken together, these results
strongly suggest that ATRA-induced autophagy is mediated
by RARα.
ATG gene depletion or chloroquine-mediated autophagy
inhibition enhances apoptosis in ATRA-treated SKBR3
cells. The antitumor effects of ATRA on SKBR3 cells are
mainly the result of a growth inhibitory and cytodifferentiating
response with subsequent induction of apoptosis.20 Indeed,
we found a time- and dose-dependent increase in caspase-3
cleavage in SKBR3 but not in MDA-MB-453 cells treated with
ATRA (Figure 5a and Supplementary Figure 2a). To evaluate
whether depletion of key autophagy genes affects ATRA-
induced cell death, we first silenced ATG7 in SKBR3 and
MDA-MB453 cells. Control and ATG7-depleted cells were
subjected to ATRA treatment before apoptosis was deter-
mined at different time points using multiple assays. In
SKBR3 cells, knocking down ATG7 clearly enhanced ATRA-
C
TR
L
A
TR
A
 d
1
A
TR
A
 d
2
C
TR
L
A
TR
A
 d
1
A
TR
A
 d
2
DAPI GFP Cherry Overlay
M
D
A
-M
B
45
3
SK
B
R
3
Figure 2 Autophagic flux in ATRA-treated SKBR3 cells. Stable Cherry-GFP-LC3B-expressing SKBR3 and MDA-MB453 cells were treated with 1 μM ATRA for 1 and 2 days.
Changes in autolysosome formation is shown by confocal microscopy analysis. Green (GFP) and red fluorescence (Cherry) signals, as well as an overlay thereof are shown.
Representative pictures from three independently performed experiments are shown
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dependent cleavage of caspase-3. This phenomenon was
particularly pronounced at day 4 (Figures 5b and c). In
contrast, no induction of cleaved caspase-3 was evident in
either control or ATG7-silenced MDA-MB453 cells (Figure 4b,
right panel). ATG7-knockdown efficiency was evaluated by
western blotting (Figure 5d). In agreement with the western
blot results, caspase-3/7 activity was significantly enhanced
in ATRA-treated SKBR3 ATG7-knockdown cells, whereas
silencing ATG7 in MDA-MB453 cells did not affect this
enzymatic activity (Figure 5e). Increased Annexin V/PI
staining in ATG7-depleted SKBR3 cells as compared with
control cells validated our previous observations (Figure 5f).
The high sensitivity of the Annexin V assay allowed the
detection of increased basal levels of apoptosis even in
untreated SKBR3 ATG7-depleted cells, although not statis-
tically significant. Based on our findings above that RARα is
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key in activating the autophagic flux, we repeated our
experiments in ATG7-knockdown and control SKBR3 cells
using the RARα agonist AM580. As observed with ATRA,
silencing ATG7 significantly enhanced AM580-induced
SKBR3 cell death (Supplementary Figures 2b and c). To
support our findings with SKBR3 ATG7-knockdown cells
above, we silenced two additional ATG genes, ATG5 and the
class III phosphatidylinositol 3-kinase VPS34 in these cells.
Following ATRA treatment, ATG5 and VPS34 depletion led to
a consistent and significant increase in SKBR3 caspase-3/7
activity as compared with scramble control transfected cells
(Figure 5g). Knockdown efficiencies for ATG5 and VPS34 are
shown in Supplementary Figure 2d. This increased cell death
response was paralleled by attenuated activation of autop-
hagy as assessed by WIPI1 transcript levels (Supplementary
Figure 2e).23 Finally, we evaluated the action of chloroquine,
a clinically relevant autophagy inhibitor, on SKBR3 cells
exposed to ATRA. We observed no marked increase in cell
death when SKBR3 cells were treated with chloroquine
alone, but in combination with ATRA, a significant increase in
cell death compared with that in cells treated with ATRA alone
was seen (Figure 5h).
As induction of autophagy was paralleled by epithelial
differentiation (Figures 1a and 3d), we were asking whether
inhibition of autophagy would impact on differentiation. To this
end, we treated SKBR3 cells with ATRA, chloroquine or a
combination thereof for 4 days and determined the expression
of the differentiation markers VE-cadherin and β-catenin by
western blotting. Blocking autophagy markedly attenuated
epithelial differentiation (Figure 6a–d). Whereas the effects of
autophagy inhibition on β-catenin levels, although significant,
were rather modest (Figure 6b, left panel), the impact on
VE-cadherin were more pronounced at least when cells were
treated with ATRA and 20 μM chloroquine (Figure 6b, right
panel). Similarly, depletion of ATG7 significantly decreased
ATRA-induced epithelial differentiation of SKBR3 cells
(Figures 6c and d). Interestingly, steady-state levels of
β-catenin and VE-cadherin were increased in ATG7-
depleted cells, although the effect is not statistically significant.
In conclusion, our results demonstrate that inhibition of
autophagy either by pharmacological or genetic means
significantly increases ATRA-mediated cell death in retinoid-
sensitive SKBR3 cells and lowers epithelial differentiation.
Discussion
In the present study, we report that ATRA induces autophagic
flux in retinoid-sensitive SKBR3 breast cancer cells via RARα.
In contrast, autophagy activation is not observed in the
retinoid-resistant MDA-MB453 cell line. Using 3-MA as a
specific inhibitor of macroautophagy,21 we were able for the
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first time to directly link macroautophagy induction to RARα
activation in breast cancer cell lines. We hypothesize that
ATRA induces autophagy only in breast cancer cells that are
not terminally differentiated and can be differentiated by
retinoids for the following reasons: (1) selective activation of
RARα by AM580 or ATRA is sufficient to induce both
autophagy and cytodifferentiation20 in SKBR3 cells, and (2)
MDA-MB453 cells are resistant to ATRA-dependent auto-
phagy and differentiation. In agreement with our hypothesis,
ATRA causes autophagy in differentiating AML cells.9–12
Additionally, NB4-resistant cells (NB4-R2), which are unable
to differentiate upon ATRA administration, do not show an
autophagic response to retinoids.11 A study by Anguiano
et al.24 demonstrated that ATRA does not promote macro-
autophagy in mouse fibroblasts, although RARα knockdown
decreased macroautophagy under basal conditions in these
terminally differentiated cells. In contrast to their study, where
depleting RARα induced 3-MA-sensitive autophagy, our
results in differentiation-competent breast cancer cells show
that RARα depletion abrogates 3-MA-sensitive proteolysis.
Work performed in HeLa cells, a cell type that cannot be
further differentiated with ATRA, indicated that retinoic acids
promote autophagosome maturation through a pathway that
does not involve the classic nuclear retinoid receptor
pathway.25 This further supports our hypothesis that RARs
are particularly important for retinoid-mediated autophagy
induction in non-terminally differentiated cells.
A novel treatment strategy for breast cancer may involve
combinations of retinoids and autophagy inhibitors with the
aim of shortening the survival of breast cancer cells. Several
groups identified a role for autophagy in response to anti-
cancer therapy, for example, camptothecin activates auto-
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software was used to quantify bands. Raw values were normalized to GAPDH. Caspase-3 levels of SKBR3 cells treated with 1 μM ATRA for 4 days were arbitrarily set to 100% as
expression levels at day 0 or 2 were undetectable or weak, respectively. (b) ATG7 and cleaved caspase-3 western blot analysis of control or shATG7-transduced SKBR3 and
MDA-MB453 cells treated with 1 μM ATRA for 2 and 4 days. Cleaved (cl.) caspase-3 expression levels were quantified as in (a). (c) Western blot analysis and quantification of
cleaved (cl.) caspase-3 in control and shATG7-transduced SKBR3 cells treated with 1 μM ATRA for 4 days. Raw values for cleaved capsase-3 were normalized to GAPDH using
the ImageJ software. Vehicle-treated control cells were arbitrarily set to 100%. Bars and s.d. are representative of five independent experiments. (d) Knockdown efficiency of
ATG7 and statistics thereof. Normalization was performed as described in (c). (e) Caspase-3/7 activity was measured using Caspase-Glo-3/7 assay from Promega. RLU values
were calculated according to manufacture's recommendations and normalized to the cell number. Values are shown for SKBR3 and MDA-MB453 control or shATG7-transduced
cells treated with 1 μM ATRA for 2 and 4 days, respectively. Standard deviations are shown from three independent experiments. (f) Annexin V/PI fluorescence-activated cell
sorting (FACS) analysis of control or ATG7-depleted SKBR3 cells at day 2, 4 and 6 of treatment with 1 μM ATRA. Bars represent five independent experiments. (g) Control, ATG5-
and VPS34 SKBR3- knockdown cells were treated and analyzed as in (e). (h) Caspase-3/7 activity of SKBR3 cells treated with ATRA, increasing concentrations of chloroquine or
a combination thereof as indicated. Analysis as in (e). Mann–Whitney U-test: *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001
Retinoid-induced autophagy in breast cancer cells
D Brigger et al
7
Cell Death and Disease
phagy, which in turn delays apoptotic cell death in noninvasive
breast cancer.26 Somewhat conflicting data exist on the role of
autophagy activation during HER2-targeted therapy with
lapatinib. On the one hand, combining lapatinib with a
pharmacological inhibitor of autophagy resulted in reduced
cell death,27 whereas on the other blocking autophagy by
beclin-1 depletion potentiated the therapeutic efficiency of
lapatinib.28 Furthermore, inhibition of epirubicin-triggered
autophagy enhances therapeutic efficiency in MDA-MB-231
breast cancer cells.29 Given the possible role for autophagy as
therapeutic strategy, it is crucial to emphasize that different
stress inducers lead either to a cytoprotective or cytotoxic
autophagy response. The outcome is clearly dependent on
the stage and type of tumor.30 These findings underline the
importance to evaluate the tumor response to autophagy
individually for each type of cancer and therapy condition. Our
results clearly support a model where blocking autophagy by
genetic and pharmacological means greatly improves ATRA
toxicity in SKBR3 cells. Therefore, it is tempting to speculate
that ATRA-induced autophagy is cytoprotective in our cell line
model. However, careful interpretation of these results is
warranted, as one of our cell death assays showed enhanced
basal levels of apoptosis in control treated SKBR3 cells. We
cannot finally exclude that SKBR3 cells are highly sensitive to
autophagy inhibition irrespective of ATRA treatment. Another
explanation might be that physiological concentrations of
ATRA, present in the fetal bovine serum (FBS), are sufficient to
induce some degree of cell death upon autophagy inhibition.
The exact mechanism how blocking autophagy contributes to
cell death in ATRA-sensitive breast cancer cells remains to be
elucidated.
Autophagy and cellular differentiation have been linked
earlier, for example, during the last step of reticulocyte
maturation, all membrane-bound organelles and ribosomes
are removed to ensure optimal hemoglobin production and
oxygen transport.31 Autophagy has been shown to contribute
to the elimination of mitochondria in this step.32–34 Similarly,
adipocytes induce autophagy, which is important for the
remodeling process.3 Furthermore, ATG5 is crucial for the
transition from the pro- to the pre-B-cell stage,35 andmonocyte
differentiation is accompanied by autophagy induction.36,37
Strategies aiming at the reactivation of differentiation
programs in the stem cell compartment of solid tumors have
great therapeutic potential.38 For example, CD44 inhibition in
breast cancer stem cells results in differentiation and
enhanced drug sensitivity.39 Similarly, ATRA-dependent differ-
entiation of cancer stem cells reduces the formation of
mammospheres and the tumor-initiating potential of certain
breast cancer cell lines.40 We now show that autophagy once
activated supports epithelial differentiation, as assessed by
β-catenin and VE-cadherin expression. These markers are
significantly downregulated upon inhibition of autophagy. In
this regard, autophagy inhibition as suggested above seems
to be rather disadvantageous, as it decreases the effects of
ATRA on differentiation. Nevertheless, the negative effect of
blocking autophagy on differentiation might be negligible given
the benefits of highly increased cell death when these two
treatments are combined.
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Figure 6 Inhibition of autophagy impacts on ATRA-induced epithelial differentiation of SKBR3 cells. (a) SKBR3 cells were treated for 4 days with 1 μM ATRA, increasing
concentrations of chloroquine or a combination thereof as indicated before western blot analysis for VE-cadherin, β-catenin, LC3B and GAPDH. (b) Quantification of β-catenin
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Materials and Methods
Chemicals. AM580 is an RARα agonist, BMS641 (3-chloro-4-[(E)-2-(5,5-dimethyl-
8-phenyl-6H-naphthalen-2-yl)ethenyl]benzoic acid; also known as UV2003) is a RARβ
agonist, whereas CD437 (6-(4-hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthale-
necarboxylic acid) is an RARγ agonist. AM580 and CD437 were purchased from Tocris
Inc. (Bristol, UK), whereas BMS641 was a kind gift of Dr. Angel R deLera
(Departamento de Química Orgánica, Universidade de Vigo, Pontevedra, Spain). 3-MA
(no. S2767)/BafA (B1793) and chloroquine (no. C6628) were purchased from Sigma-
Aldrich (Buchs, Switzerland) and Seleckchem (Huston, TX, USA), respectively.
Cell lines and culture conditions. Human breast cancer lines MDA-
MB-453 and SKBR3 were cultured in DMEM/F12 supplemented with 5% FBS, 50 U/ml
penicillin and 50 μg/ml streptomycin in humidified atmosphere containing 5% CO2 at
37 °C. ATRA- and the RAR-specific agonists were used at 0.1 or 1 μM.
Long-lived protein degradation assay. Cells were seeded in 24-well
plates and radiolabeled with 0.2 μCi 14C-valine (L-[U-14-C]valine; code CFB.75;
Amersham, Glattbrugg, Switzerland) per ml per well for 2 days in combination with
ATRA or agonist/antagonists. Cells were washed with PBS to remove free
radioactivity, and chased in 0.5 ml complete DMEM/F12 supplemented with 10 mM
cold valine for 1 h. Short-lived proteins were washed out and cells were treated for
additional 5.5 h in complete control medium DMEM/F12 supplemented with 200 nM
BafA or DMSO as control. Cells were scraped in their media and further processed
as described in Brigger et al.11 with the following changes: after the cold chase
phase, DMSO- and ATRA-treated cells were incubated in complete control medium
DMEM/F12 in the presence or absence of 200 nM BafA or 10 mM 3-MA.
Radioactivity was determined by liquid scintillation counting in triplicates. The
degradation rate for long-lived proteins was calculated as the percentage of
radioactivity in the TCA-soluble fraction relative to the total radioactivity in non-
soluble fractions. To calculate the BafA-sensitive autophagy, the values were
subtracted from the corresponding sample treated with BafA.
Western blotting. Whole-cell extracts were prepared using 8 M urea buffer with
0.5% Triton X-100, supplemented with proteinase inhibitor cocktail (complete; Roche,
Basel, Switzerland). Total protein (25–80 μg) was separated on a 12% SDS-
polyacrylamide gel and transferred to a PVDF membrane. Blots were incubated with
primary antibody overnight at 4 °C, washed and incubated with secondary anti-mouse or
anti-rabbit antibodies for 1 h at room temperature protected from light. Primary
antibodies used were anti-LC3B (NB600-1384; Novus Biologicals, Abingdon, UK),
cleaved caspase-3 (9661; Cell Signaling, Danvers, MA, USA), VE-CAD (no. 2158; Cell
Signaling), β-catenin (9562; Cell Signaling), VPS34 (no. NB110-87320SS; Novus
Biologicals), RARα (c-551; Santa Cruz, Heidelberg, Germany) and anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (MAB374; Milipore, Vienna, Austria). Secondary
antibodies were used as described in Brigger et al.11
Generation of knockdown and Cherry-GFP-LC3B-expressing cell lines pLKO.1
lentiviral vectors expressing small hairpin RNAs (shRNAs) targeting RARα, ATG7,
ATG5 and VPS34 or a non-targeting shRNA control (SHC002) were purchased from
Sigma-Aldrich. A lentiviral vector expressing Cherry-GFP-LC3B was provided by
Dr. MS Soengas (Melanoma Laboratory, Madrid, Spain). Lentiviral production and
transduction of SKBR3 cells was carried out as described.11 Transduced cell
populations were selected for 4 days using 1.5 μg/ml puromycin.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde (PFA) or
with ice-cold 100% methanol for 4 min and then washed with PBS containing 0.5%
glycine. Subsequently, cells were permeabilized with Triton X-100 for PFA fixed cells.
Anti-β-catenin (9562; Cell Signaling) and anti-LC3B (3868; Cell Signaling) antibody were
incubated for 1 h at room temperature followed by washing steps with PBS containing
0.1% Tween (PBS-T). Cells were incubated with the secondary antibody (anti-rabbit,
111-096-045; Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room
temperature. Prior mounting in fluorescence mounting medium (S3032; Dako) cells
were washed three times with PBS-T. Fluorescence microscopy of GFP-Cherry-LC3B
expressing SKBR3 and MDA-MB-453 human breast cancer cell lines was performed as
described in Brigger et al.11 Images were taken on a confocal microscope Olympus
FluoView-1000 (Olympus, Volketswil, Switzerland) at x63 magnification.
Annexin V/PI FACS analysis. Cells where harvested at indicated time
points, washed using Annexin V buffer (BD Biosciences, Allschwil, Switzerland) and
stained with Annexin V-FITC (BioLegend, Fell, Germany). Prior FACS analysis, PI
(Sigma-Aldrich) was added at a final concentration of 2.5 μg/ml. Analysis was
acquired on an LSR II (BD Biosciences) and analyzed using the FlowJo software.
Caspase-3/7 activity assay. Caspase-3/-7 activity was determined using
the Caspase-Glo-3/7 assay (Promega, Dübendorf, Switzerland) according to the
manufacturer’s description. As cell number greatly differed between treated and
untreated cells, relative luminescence values (RLUs) were normalized to results
obtained from an Alamarblue assay (LifeTechnologies, Zug, Switzerland).
Real-time qRT-PCR. RNA extraction, RT-PCR and real-time qRT-PCR (qPCR)
and data analysis were performed as described.11 Gene Expression Assay for
WIPI1 and MAP1LC3B (microtubule-associated protein 1 light chain 3) used in a
96-well format on the StepOne plus sequence detection system were
Hs00215872_m1 and Hs00797944_s1, respectively (Applied Biosystems, Rotkreuz,
Switzerland). HMBS ABL1 primers where 5′-TGGAGATAACACTCTAAGCATAAC
TAAAGGT-3′ and 5′-GATGTAGTTGCTTGGGACCCA-3′ and probe was 5′-FAM-
CCATTTTTGGTTTGGGCTTCACACCATT-TAMRA-3′.
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